Valuation : Poxel

Market Cap 12.57M 14.6M 11.81M 10.78M 20.24M 1.39B 20.39M 140M 54.43M 705M 54.83M 53.64M 2.33B P/E 2023
-0.52x
P/E 2024 -0.36x
Enterprise Value 79.65M 92.51M 74.79M 68.27M 128M 8.8B 129M 886M 345M 4.46B 347M 340M 14.78B EV / Sales 2023
33.3x
EV / Sales 2024 11.2x
Free-Float
94.27%
Yield 2023 *
-
Yield 2024 -
1 day+0.25%
1 week-5.84%
Current month+0.25%
1 month+0.50%
3 months-12.01%
6 months-22.05%
Current year-13.89%
1 week 0.2
Extreme 0.195
0.21
1 month 0.19
Extreme 0.1926
0.25
Current year 0.19
Extreme 0.1926
0.48
1 year 0.19
Extreme 0.1926
0.48
3 years 0.12
Extreme 0.115
0.95
5 years 0.12
Extreme 0.115
6.84
10 years 0.12
Extreme 0.115
13.8
Manager TitleAgeSince
Chief Executive Officer 59 09/06/2026
Director of Finance/CFO - 30/11/2022
Corporate Officer/Principal - 30/04/2023
Director TitleAgeSince
Chairman - 30/07/2025
Director/Board Member - 30/07/2025
Director/Board Member - 30/07/2025
Date Insider Type Main position Quantity % Market Cap. Importance
04/02/22 Exercice

Founder

67,000 0.2334%
04/02/22 Exercice

Founder

6,666 0.0232%
30/01/21 Free

Founder

25,263 0.0888%
Change 5-day change 1-year change 3-year change Capi.($)
+0.25%-5.84%-35.93%-65.56% 12.54M
-1.66%-4.96%+49.84%+88.43% 68.13B
+0.78%+2.11%+45.66%+89.85% 63.6B
+1.31%+1.81%+37.52%+12.07% 25.57B
+2.77%-1.74%-16.16%+456.51% 26.6B
-0.46%-9.94%+0.98%-15.98% 25.52B
-9.71%-0.36%+245.87%+377.68% 18.23B
-0.40%+0.33%+29.17%-19.73% 19.69B
-1.25%-6.12%+1.03%+541.83% 15.16B
+0.35%+0.16%+46.96%+144.04% 13.54B
Average -0.79%-3.92%+40.49%+160.91% 27.61B
Weighted average by Cap. -0.60%-2.34%+45.50%+146.51%

Financials

2023 2024
Net sales 1.98M 2.3M 1.86M 1.7M 3.19M 219M 3.21M 22.04M 8.58M 111M 8.64M 8.45M 368M 6.64M 7.71M 6.23M 5.69M 10.69M 733M 10.76M 73.84M 28.73M 372M 28.94M 28.31M 1.23B
Net income -35.09M -40.75M -32.95M -30.08M -56.5M -3.88B -56.91M -390M -152M -1.97B -153M -150M -6.51B -18.3M -21.26M -17.19M -15.69M -29.47M -2.02B -29.69M -204M -79.24M -1.03B -79.83M -78.09M -3.4B
Net Debt 46.42M 53.92M 43.59M 39.79M 74.75M 5.13B 75.29M 517M 201M 2.6B 202M 198M 8.61B 67.08M 77.91M 62.99M 57.5M 108M 7.41B 109M 746M 290M 3.76B 293M 286M 12.45B
Logo Poxel
Poxel is a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare disorders. For the treatment of NASH, PXL065 (deuterium-stabilized R-pioglitazone) met its primary endpoint in a streamlined Phase 2 trial (DESTINY-1). In rare diseases, development of PXL770, a first-in-class direct adenosine monophosphate-activated protein kinase (AMPK) activator, is focused on the treatment of adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD). TWYMEEG® (Imeglimin), Poxel's first-in-class product that targets mitochondrial dysfunction, is marketed for the treatment of type 2 diabetes in Japan by Sumitomo Pharma and Poxel expects to receive royalties and sales-based payments. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.
Employees
5
Date Price Change Volume
01/09/26 0.2015 +0.25% 27,901
31/08/26 €0.2010 0.00% 442,611
28/08/26 €0.2010 -0.25% 265,811
27/08/26 €0.2015 -2.66% 214,820
26/08/26 €0.2070 -3.27% 439,543
  1. Stock Market
  2. Stocks
  3. POXEL Stock